Adaptive Biotechnologies (ADPT)
NASDAQ:ADPT
Want to see ADPT full AI Analyst Report?
ADPT Stock Chart & Stats
$14.47
-$0.27(-3.80%)
At close: 4:00 PM EST
$14.47
-$0.27(-3.80%)
Day’s Range― - ―
52-Week Range$9.96 - $20.76
Previous CloseN/A
Volume480.81K
Average Volume (3M)2.66M
Market Cap
$2.78B
Enterprise Value$2.82B
Total Cash (Recent Filing)$218.33M
Total Debt (Recent Filing)$208.18M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 05, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding160,044,390
10 Day Avg. Volume4,464,744
30 Day Avg. Volume2,659,524
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)11.26
Price to Sales (P/S)8.90
P/FCF Ratio-50.34
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue9.53
Enterprise Value/Gross Profit12.67
Enterprise Value/Ebitda-127.83
Forecast
1Y Price Target
$20.17Price Target Upside39.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$287.20M
Bulls Say, Bears Say
Bulls Say
Rapid MRD Revenue And Clinical AdoptionSustained double‑digit MRD volume and revenue growth, rising clinician adoption and elevated ordering clinicians create durable topline momentum. Higher test penetration and repeat utilization drive recurring revenue, deepen payer engagement, and create a structural growth runway over multiple years.
High And Improving Sequencing Gross MarginsSubstantially higher sequencing margins from scale and NovaSeq X efficiencies indicate structural unit economics improvements. Durable margin expansion improves operating leverage as volumes grow, supporting the path to adjusted EBITDA and sustainable profitability without depending solely on one‑off items.
Stronger Liquidity And Strategic Financing ActionsThe sizeable convertible issuance and allocation to repay prior obligations materially reshapes the capital structure, reducing near‑term creditor pressures and providing flexible funding. This strengthens the balance sheet and funds MRD investment, increasing resilience while the company pursues profitability targets.
Bears Say
Negative Operating Cash Flow And Free Cash FlowPersistent negative operating and free cash flow, albeit improved, indicate the business is not yet self‑funding growth. Continued cash burn requires ongoing financing or discipline; failure to convert margin gains into consistent positive cash flow would constrain investment, capital returns, and strategic optionality.
Material Leverage For A Loss‑making CompanyMeaningful indebtedness while the company remains unprofitable increases financial rigidity and refinancing risk. Interest and covenant considerations limit flexibility to invest in commercial expansion or immune medicine R&D, and elevate vulnerability to reimbursement setbacks or slower MRD uptake.
Revenue Concentration And Weak Immune‑medicine SegmentHeavy dependence on MRD creates single‑product concentration risk; the underperforming immune medicine business reduces diversification and upside from data/licensing streams. A setback in MRD reimbursement, adoption, or milestone timing would disproportionately compress revenue and margins.
Adaptive Biotechnologies News
ADPT FAQ
What was Adaptive Biotechnologies’s price range in the past 12 months?
Adaptive Biotechnologies lowest stock price was $9.96 and its highest was $20.76 in the past 12 months.
What is Adaptive Biotechnologies’s market cap?
Adaptive Biotechnologies’s market cap is $2.78B.
When is Adaptive Biotechnologies’s upcoming earnings report date?
Adaptive Biotechnologies’s upcoming earnings report date is Aug 05, 2026 which is in 42 days.
How were Adaptive Biotechnologies’s earnings last quarter?
Adaptive Biotechnologies released its earnings results on May 05, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.03.
Is Adaptive Biotechnologies overvalued?
According to Wall Street analysts Adaptive Biotechnologies’s price is currently Undervalued.
Does Adaptive Biotechnologies pay dividends?
Adaptive Biotechnologies does not currently pay dividends.
What is Adaptive Biotechnologies’s EPS estimate?
Adaptive Biotechnologies’s EPS estimate is -0.14.
How many shares outstanding does Adaptive Biotechnologies have?
Adaptive Biotechnologies has 160,044,390 shares outstanding.
What happened to Adaptive Biotechnologies’s price movement after its last earnings report?
Adaptive Biotechnologies reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went up 4.717%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies?
Currently, no hedge funds are holding shares in ADPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adaptive Biotechnologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.17 (39.37% Upside)
$20.17 (39.37% Upside)
Blogger Sentiment
Neutral
ADPT Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 23.1%
Last 30 Days ▲ 23.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.16%
12-Months-Change
Fundamentals
Return on Equity
-24.26%
Trailing 12-Months
Asset Growth
-0.96%
Trailing 12-Months
Company Description
Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
ADPT Company Deck
ADPT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrays a company with strong, broad-based MRD momentum: double-digit revenue growth, volume records, margin expansion, a raised MRD revenue guide, growing backlog, and improving MRD profitability. Challenges are concentrated in the immune medicine business (declining revenue and losses), company-level net loss and elevated operating expenses, milestone lumpiness, and reimbursement/regulatory uncertainty. Taken together the positives—notably durable clinical adoption, pricing gains, margin improvement, a large and growing backlog, and a solid cash position—outweigh the negatives, which are largely isolated or acknowledged with mitigations in progress.View all ADPT earnings summariesADPT Stock 12 Month Forecast
Average Price Target
$20.17
▲(39.37% Upside)
Technical Analysis
Immunovant
―
Arcutis Biotherapeutics
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Recursion Pharmaceuticals
―
Ownership Overview
3.48% Insiders
21.96% Mutual Funds
43.18% Other Institutional Investors
16.77% Public Companies and
Individual Investors